TABLE OF CONTENTS
1 INTRODUCTION
1.1 DEFINITION
1.2 SCOPE OF STUDY
1.2.1 RESEARCH OBJECTIVE
1.2.2 ASSUMPTIONS & LIMITATIONS
1.2.2.1 ASSUMPTIONS
1.2.2.2 LIMITATIONS
1.3 MARKET STRUCTURE:
2 RESEARCH METHODOLOGY
2.1 RESEARCH PROCESS:
2.2 PRIMARY RESEARCH
2.3 SECONDARY RESEARCH:
3 MARKET DYNAMICS
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 MACROECONOMIC INDICATORS
4 MARKET FACTOR ANALYSIS
4.1 PORTERS FIVE FORCES MODEL
4.2 BARGAINING POWER OF SUPPLIERS
4.3 BARGAINING POWER OF BUYERS
4.4 THREAT OF NEW ENTRANTS
4.5 THREAT OF SUBSTITUTES
4.6 INTENSITY OF RIVALRY
5. AMERICAS INSOMNIA MARKET, BY TYPES OF THERAPY
5.1 PHARMACOLOGICAL THERAPY
5.1.1 BENZODIAZEPINES
5.1.2 NON-BENZODIAZEPINES
5.1.3 MELATONIN RECEPTOR AGONISTS
5.1.4 OTHER
5.2 NON PHARMACOLOGICAL THERAPY
5.2.1 RELAXATION THERAPY
5.2.2 COGNITIVE BEHAVIORAL THERAPY
5.2.3 SLEEP HYGIENE EDUCATION
5.2.4 STIMULUS CONTRO
5.2.5 PARADOXICAL INTENTION
5.2.6 OTHER
6. AMERICAS INSOMNIA MARKET, BY DRUG FORMULATION
6.1 CAPSULES
6.2 TABLET
6.3 OTHERS.
7. AMERICAS INSOMNIA MARKET, BY TYPES OF DISEASE
7.1 POOR QUALITY OF SLEEP
7.2 SLEEP MAINTENANCE
7.3 OTHER.
8. AMERICAS INSOMNIA MARKET, BY REGION
8.1 INTRODUCTION
8.2 NORTH AMERICA
8.2.1 US
8.2.2 Canada
8.2.1 SOUTH AMERICA
9. COMPETITIVE LANDSCAPE
9.1 MAJOR STRATEGIES ADOPTED BY MARKET PLAYERS
8.1.1 STRATEGIC PARTNERSHIP
9.1.2 MERGER & ACQUISITION
10 COMPANY PROFILE
10.1 EISAI, CO.
10.1.1 OVERVIEW
10.1.2 PRODUCT OVERVIEW
10.1.3 FINANCIALS
10.1.4 KEY DEVELOPMENTS
10.2 MERCK & CO INC
10.2.1 OVERVIEW
10.2.2 PRODUCT OVERVIEW
10.2.3 FINANCIALS
10.2.4 KEY DEVELOPMENTS
10.3 SANOFI
10.3.1 OVERVIEW
10.3.2 PRODUCT OVERVIEW
10.3.3 FINANCIALS
10.3.4 STRATEGY
10.3.5 KEY DEVELOPMENT
10.4 TAKEDA PHARMACEUTICAL COMPANY
10.4.1 OVERVIEW
10.4.2 PRODUCT OVERVIEW
10.4.3 FINANCIALS
10.4.4 KEY DEVELOPMENTS
10.5 PFIZER, INC.
10.5.1 OVERVIEW
10.5.2 PRODUCT OVERVIEW
10.5.3 FINANCIALS
10.5.4 KEY DEVELOPMENTS
10.6 OTHERS